Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Albireo's constipation asset plugs Ferring's pipeline

This article was originally published in Scrip

Executive Summary

Swiss firm Ferring says it has signed one of its biggest licensing deals ever (although it won't provide figures) in acquiring rights to a first-in-class compound for constipation. It says it has paid a significant upfront licensing fee, milestones and tiered double-digit royalties and will take on the costs of development for elobixibat from Albireo, the gastro-enterology focused Swedish firm that was spun out of AstraZeneca in 2008.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC017974

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel